IMVT
Immunovant, Inc.NASDAQHealthcare$24.50-2.39%ClosedMarket Cap: $4.99B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.58
P/S
0.00
EV/EBITDA
-8.46
DCF Value
$4.62
FCF Yield
-8.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.8%
ROA
-44.1%
ROIC
-49.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $0.00 | -Infinity% | $-114.4M | $-110.6M | $-0.61 | — |
| Q2 2026 | $0.00 | -Infinity% | $-131.8M | $-126.5M | $-0.73 | — |
| Q1 2026 | $0.00 | NaN% | $-127.2M | $-120.6M | $-0.71 | — |
| Q4 2025 | $0.00 | NaN% | $-113.8M | $-106.4M | $-0.64 | — |
| FY 2025 | $0.00 | NaN% | $-438.2M | $-413.8M | $-2.73 | — |
| Q3 2025 | $0.00 | NaN% | $-114.3M | $-111.1M | $-0.76 | — |
| Q2 2025 | $0.00 | NaN% | $-115.7M | $-109.1M | $-0.74 | — |
| Q1 2025 | $0.00 | NaN% | $-94.3M | $-87.2M | $-0.60 | — |
| Q4 2024 | $0.00 | NaN% | $-80.9M | $-75.3M | $-0.52 | — |
| FY 2024 | $0.00 | NaN% | $-270.2M | $-259.3M | $-1.88 | — |
| Q3 2024 | $0.00 | NaN% | $-61.6M | $-51.4M | $-0.36 | — |
| Q2 2024 | $0.00 | NaN% | $-61.8M | $-58.7M | $-0.45 | — |